Suchergebnisse - "Pistilli, B"

PubPharm (33)

1

Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes

enthalten in: ESMO open | 2024

von Franzoi, M. | Aupomerol, M. | Havas, J. | +17

2

Is controlled ovarian stimulation safe in patients with hormone receptor-positive breast cancer receiving neoadjuvant chemotherapy?

enthalten in: ESMO open | 2024

von Benvenuti, C. | Laot, L. | Grinda, T. | +3

3

Optimizing the potential of antibody-drug conjugates in oncology

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2023

von Mosele, F. | Montagnac, G. | Pistilli, B. | +1

4

Are ERBB2 mutations a 'ready for routine use' target in patients with metastatic breast cancer?

enthalten in: ESMO open | 2023

von Grinda, T. | Pistilli, B.

5

Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer

enthalten in: Cancer treatment reviews | 2023

von Epaillard, N. | Bassil, J. | Pistilli, B.

6

Deep Learning Allows Assessment of Risk of Metastatic Relapse from Invasive Breast Cancer Histological Slides

enthalten in: bioRxiv.org | 2022

von Garberis, I. | Gaury, V. | Saillard, C. | +29

7

Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer : results from a phase II basket study

enthalten in: ESMO open | 2022

von Boni, V. | Pistilli, B. | Braña, I. | +15

8

Breast Cancer Patients' Experience and Wishes Regarding Communication on Sexual Health : The BEROSE Study

enthalten in: Cancer investigation | 2022

von Aupomerol, M. | Chaltiel, D. | Pautier, P. | +12

9

Factors associated with enrolment in clinical trials among women with early-stage breast cancer

enthalten in: ESMO open | 2022

von Presti, D. | Havas, J. | Soldato, D. | +15

10

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients : study design of PADA-1

enthalten in: BMJ open | 2022

von Berger, F. | Marce, M. | Delaloge, S. | +106